Collection's Items (Sorted by Submit Date in Descending order): 81 to 100 of 960
| Issue Date | Title | Author(s) |
| 2024-10 | Molecular docking and in silico adme(t) evaluation of selective phytochemical inhibitors of vegf2 target for the treatment of diabetic retinopathy | Murugesan, Sankaranarayanan |
| 2024-11 | Decentralized control of ideal ternary reactive distillation column with inert | Murugesan, Sankaranarayanan |
| 2024-08 | Identification of potential inhibitors from medicinal plant-based phytochemicals for the influential c4 target of diabetic retinopathy by molecular docking studies | Murugesan, Sankaranarayanan |
| 2025-02 | In silico studies of phytoconstituents to identify potential inhibitors for erα protein of breast cancer | Murugesan, Sankaranarayanan |
| 2025-04 | Pharmacoinformatics-based prediction of checkpoint kinase-1 inhibitors from momordica charantia linn. for cancer | Murugesan, Sankaranarayanan |
| 2024 | Therapeutic strategies to modulate gut microbial health: approaches for sarcopenia management | Shrivastava, Richa |
| 2023-12 | First demonstration of gan hemt-based handheld system for noninvasive detection of traumatic brain injury using saliva | Taliyan, Rajeev |
| 2024 | Gene therapy: advocacies, perspectives, and ethical provocations | Taliyan, Rajeev |
| 2024 | Role of phytopharmaceuticals as adjuncts in treatment of glioblastoma multiforme | Taliyan, Rajeev |
| 2024 | Bio-Interface Analysis and Detection of Aβ using GaN HEMT-based Biosensor | Taliyan, Rajeev |
| 2024-04 | Development of biotin decorated Olaparib loaded cationic lipopolymeric hybrid nanoparticle and evaluation of its anticancer effect and pharmacokinetics for triple negative breast cancer | Taliyan, Rajeev |
| 2024 | Meander-gated dual cap gan hemt-based portable noninvasive covid-19 detection platform | Taliyan, Rajeev |
| 2024-06 | Novel gene therapy approaches for targeting neurodegenerative disorders: focusing on delivering neurotrophic genes | Taliyan, Rajeev |
| 2024-08 | Dynamic endocannabinoid-mediated neuromodulation of retinal circadian circuitry | Taliyan, Rajeev |
| 2024 | Targeting circadian protein rev-erbα to alleviate inflammation, oxidative stress, and enhance functional recovery following brain trauma | Taliyan, Rajeev |
| 2024-08 | Label-free GaN HEMT-based biosensing platform for interferon-γ detection | Taliyan, Rajeev |
| 2024-06 | Pharmacokinetic and Biodistribution Studies of Camel Milk Casein Nanoparticles Loaded Sorafenib in Swiss Albino Mice | Taliyan, Rajeev; Dubey, Uma S. |
| 2024-11 | Immunological challenges and opportunities in glioblastoma multiforme: A comprehensive view from immune system lens | Singhvi, Gautam; Taliyan, Rajeev |
| 2024-12 | Neuroprotective potential of Epigenetic modulators, its regulation and therapeutic approaches for the management of Parkinson's disease | Taliyan, Rajeev |
| 2025-01 | Millions of people worldwide are negatively impacted by a diverse range of brain conditions known as neurodegenerative diseases. The work reports a GaN HEMT-based biosensing system for the early detection and monitoring of neurodegenerative disease biomarkers in clinically relevant concentration ranges. The developed system offers a high sensitivity of 19.40 µA/pg/ml, 0.52 mA/pg/ml, 0.69 mA/ng/ml, 0.13 mA/pg/ml, 23.66 µA/pg/ml, and 23.85 µA/pg/ml for the detection of UCH-L1, GFAP, S100B, IL-6, Aβ, and IFN-γ respectively. The proposed biofunctionalization assay has an excellent specificity and selectivity, signal-to-noise ratio of 1:16, 1:23, and 1:38 for UCH-L1, GFAP, and S100B detection respectively with a LoD of 0.06 fg/ml. The platform has good repeatability with an average sensitivity of 19.41 µA/pg/ml, 0.524 mA/pg/ml, and 0.704 mA/ng/ml for UCH-L1, GFAP, and S100B detection respectively. The sensors have a very good shelf-life for a storage time of 35 days with reductions of 1.39 %, 1.72 %, and 2.05 % in sensor response and 2.88 %, 2.76 %, and 2.96 % in sensitivity for UCH-L1, GFAP, and S100B respectively. The coefficient of variation (CV) values for conventional and meander-gated GaN HEMT biosensors were found to be ∼0.038 and ∼0.026 respectively. A slight variation of ∼4.41 % in sensor response when the sensor was reused clearly demonstrates the sensor’s reusability. A very high resolution with detection capability in the ultra-low concentration of fg/ml with good linearity and quantifiable sensor response which is a key requirement for early-stage detection of diseases has been observed for sensor design with source-to-drain distance () of 10 µm. Thus, the platform capability and suitability for early detection and prognosis of neurodegenerative disease detection and monitoring have been demonstrated. Further, the system can be imperative in patient screening in clinical, sports, and warfare for CT or MRI scan requirements. | Taliyan, Rajeev |
Collection's Items (Sorted by Submit Date in Descending order): 81 to 100 of 960
